Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection

The combination of the beta-lactam tebipenem and the beta-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus in vitro. Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection. The results suggest that tebipenem-avibactam presents an attractive oral drug candidate pair for the treatment of M. abscessus pulmonary disease and could inform the design of clinical trials. The combination of the beta-lactam tebipenem and the beta-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus in vitro. Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection.

Automated summary

The combination of tebipenem and avibactam, both belonging to the beta-lactam class, exhibits strong bactericidal activity against Mycobacterium abscessus in vitro. In a mouse model of M. abscessus lung infection, the combination of their respective oral prodrugs, tebipenem-pivoxil and avibactam ARX-1796, showed efficacy. These findings suggest that tebipenem-avibactam is a promising oral drug candidate for the treatment of M. abscessus pulmonary disease and could guide the design of clinical trials.